Millions of Medicare beneficiaries who rely on expensive medications for cancer, diabetes, and other chronic conditions stand to pay less starting in 2027. The Centers for Medicare and Medicaid Services (CMS) has set Maximum Fair Prices for 15 additional drugs, projecting roughly $685 million in savings for enrollees in that year alone. Combined with the first 10 drugs that received negotiated prices effective in 2026, the program now covers 25 medications, and CMS estimates the negotiated rates will cut costs by an average of 44 percent, delivering approximately $12 billion in net savings across the first two years.
How 25 negotiated drug prices reshape out-of-pocket costs
The financial relief is not abstract. For enrollees filling prescriptions for drugs that treat blood cancers, autoimmune disorders, and heart disease, the difference between a list price and a Maximum Fair Price can determine whether they pick up the medication at all. In its description of the second negotiation cycle, CMS highlighted projected enrollee savings for 15 widely used products, emphasizing that these reduced prices for cancer and chronic disease treatments are intended to reach people living on fixed incomes.
CMS tied the second-cycle prices to a January 1, 2027 effective date, meaning pharmacies and Part D plans will begin applying the lower rates at the start of that plan year. For beneficiaries, the change will show up in several ways: lower deductibles met more quickly, reduced coinsurance on each refill, and fewer instances where a single prescription pushes them into the coverage gap. Because these 25 drugs account for a disproportionate share of Part D spending, even modest percentage reductions can translate into hundreds or thousands of dollars per patient annually.
A reasonable expectation is that lower prices will lead more patients to fill their prescriptions rather than abandon them at the pharmacy counter. Prescription abandonment, where a patient declines to pick up a medication after seeing the copay, runs highest among specialty drugs with steep cost-sharing. If the 44 percent average price reduction translates into proportionally lower copays, abandonment rates for these therapeutic areas could drop measurably within the first 18 months. CMS prescription drug event files, which track every Part D transaction, would capture that shift in real time.
No published CMS analysis has yet modeled that specific outcome, so projections about adherence remain inferential. Still, the directional logic is straightforward: when drugs cost less, more people take them. For clinicians, that could mean more consistent access to oral cancer therapies, immunomodulators, and cardiovascular agents that are central to modern treatment regimens. For plans, improved adherence may offset some of the upfront price concessions if it prevents costly hospitalizations linked to uncontrolled disease.
CMS data files and GAO oversight behind the $12 billion estimate
The $12 billion net savings figure and the 44 percent average reduction both originate from CMS calculations built on the Maximum Fair Price for each drug. The agency’s program page offers negotiated-price files with 30-day equivalent supply pricing and National Drug Code-level detail, allowing independent researchers and plan sponsors to compare the new prices against historical benchmarks.
Those files make the negotiation program unusually transparent by Medicare standards. Analysts can see not only the headline Maximum Fair Price but also how it varies by dosage form and strength, then map that information onto utilization data. That is the basis for CMS’s aggregate savings estimates: multiplying expected volume by the difference between previous prices and the negotiated amounts. While the topline numbers are large, the actual impact will vary widely by beneficiary depending on their specific drug regimen and plan design.
Separately, the Government Accountability Office (GAO) reviewed the CMS Final Guidance for Initial Price Applicability Year 2027 and classified it as a major rule under report B-336761. That review covers how manufacturers must put the Maximum Fair Price into effect during 2026 and 2027, including timelines for updating contracts and ensuring that pharmacies can process claims at the new rates. The GAO designation underscores that the guidance has significant economic impact and warrants congressional notice and oversight.
However, the GAO filing does not include raw enforcement data or compliance audits, leaving a gap in public knowledge about how smoothly manufacturers, wholesalers, and plans will execute the new prices at the pharmacy level. Until CMS releases implementation metrics, questions will remain about potential delays, disputes over price calculations, or uneven application of the Maximum Fair Price across different dispensing channels.
Expansion to Part B drugs and the next negotiation cycle
The program is already expanding beyond Part D. CMS announced 15 drugs selected for a third negotiation cycle, and for the first time that round includes Part B products, which are typically administered in physician offices or hospital outpatient departments. In its announcement of the third cycle, CMS described how these newly selected Part B and Part D drugs will move through a similar negotiation and implementation timeline, with Maximum Fair Prices to follow.
Bringing Part B drugs into the negotiation framework marks a significant shift because these medications often carry very high per-dose costs and are reimbursed under a different statutory formula. For patients receiving infusions or injections for cancer, autoimmune disease, or other serious conditions, negotiated prices could eventually lower coinsurance amounts that are currently calculated as a percentage of the drug’s charge.
Together, the first three negotiation cycles signal a broader restructuring of how Medicare pays for high-cost therapies. The near-term numbers-$685 million in projected enrollee savings in 2027 and $12 billion in net savings across the first 25 drugs-are substantial on their own. The longer-term test will be whether these negotiated prices improve adherence, reduce financial hardship, and maintain access to breakthrough treatments as more drugs come under the program’s umbrella.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
